What is Aqtual?
Aqtual, Inc. operates at the forefront of biotechnology, specializing in the development of advanced products for chronic disease management and oncology. The company's core innovation lies in its proprietary platform that evaluates complex biological markers—specifically protein regulation, epigenetics, and transcriptomics—solely through cell-free DNA fragments extracted from blood samples. This approach represents a significant departure from traditional diagnostic methodologies, offering a more efficient and robust framework for real-time monitoring of disease progression and treatment efficacy. By overcoming the inherent limitations of legacy cell-free DNA technologies, Aqtual is effectively democratizing access to high-fidelity diagnostic data, which is essential for personalized medicine and improved patient outcomes in oncology and beyond.
How much funding has Aqtual raised?
Aqtual has raised a total of $47M across 2 funding rounds:
Series A
$16M
Series B
$31M
Series A (2023): $16M with participation from Genoa Ventures and Manta Ray Ventures
Series B (2025): $31M led by Yu Galaxy, Genoa Ventures, Manta Ray Ventures, and BOLD Capital Partners
Key Investors in Aqtual
Yu Galaxy
A Palo Alto-based venture capital firm focused on partnering with entrepreneurs to develop impactful technologies and category-defining companies in the medical and AI sectors.
Genoa Ventures
An investment firm specializing in early-stage companies that innovate at the intersection of biology and technology, with a focus on bioconvergence.
Manta Ray Ventures
An early-stage venture capital fund that provides patient capital and strategic resources to mission-driven founders tackling significant global challenges.
What's next for Aqtual?
With the successful closure of this major enterprise-level funding, Aqtual is poised to accelerate its clinical development programs and expand its technological footprint. The strategic focus will likely shift toward scaling the platform's analytical capabilities and pursuing regulatory milestones that will facilitate broader clinical adoption. As the company transitions into this next phase of maturity, the emphasis will remain on leveraging its unique cell-free DNA insights to redefine standards in chronic disease management. Investors are closely watching how Aqtual will utilize this capital to solidify its competitive position against established diagnostic incumbents, particularly as the demand for non-invasive, high-precision medical tools continues to surge globally.
See full Aqtual company page
